- Home
- NBIX
as 05-30-2025 4:00pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 12.0B | IPO Year: | 1996 |
| Target Price: | $163.20 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.96 | EPS Growth: | -17.91 |
| 52 Week Low/High: | $84.23 - $157.98 | Next Earning Date: | 05-05-2025 |
| Revenue: | $2,412,600,000 | Revenue Growth: | 21.73% |
| Revenue Growth (this year): | 15.99% | Revenue Growth (next year): | 14.93% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | Director | May 27 '25 | Sell | $120.38 | 9,613 | $1,157,211.02 | 514,596 | |
| RASTETTER WILLIAM H | NBIX | Director | May 5 '25 | Sell | $110.20 | 30,000 | $3,305,952.00 | 37,491 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
Insider Monkey
3 days ago
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched
MT Newswires
3 days ago
Neurocrine Reports Positive Data in Mid-Stage Schizophrenia Trial
PR Newswire
3 days ago
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
Simply Wall St.
9 days ago
Exploring 3 High Growth Tech Stocks In The US Market
MT Newswires
15 days ago
Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures
PR Newswire
16 days ago
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
PR Newswire
16 days ago
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.